Newly launched TCR company ALKemist Bio announces a €6.9M Investment Round to develop first-in-class TCR Cell Therapy for ALK-Positive Tumors
Newly launched TCR company ALKemist Bio announces a €6.9M Investment Round to develop first-in-class TCR Cell Therapy for ALK-Positive Tumors Turin, Italy […]